The single-target molecular targeted drugs, EGFR-TKI inhibitors, Erysart and Troche, have opened new avenues of treatment for advanced non-small cell lung cancer, from which many patients have benefited, but the…
Typical case presentation A 61-year-old male patient was admitted to the hospital with “right upper lung nodule found on physical examination for 1 year”. He had no other complaints of…
February 2011 Three major international academic organizations: IASLC, ATS, and ERS jointly published a new international multidisciplinary classification of lung adenocarcinoma. Oncologists, respiratory pathologists, pathologists, radiologists, molecular biologists, and thoracic…
The patient is a male, 50 years old, “right lung adenocarcinoma with multiple mediastinal lymph node metastases”, diagnosed definitively in 2013, with biopsy specimen genetic test results: negative for EGFR…
The place of molecularly targeted drugs in the treatment of lung adenocarcinoma is becoming increasingly evident, but in practice, far less attention has been paid to EGFR mutation detection. Since…
In China, about 400,000 people die from lung cancer each year, topping the list of deaths caused by all types of cancer. Lung adenocarcinoma is the most common type of…
The survival time of patients with invasive lung adenocarcinoma is related to the size and location of the tumor, the presence or absence of distant metastases, and the treatment method,…
At the beginning of 2011, the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society (IASLC, ATS, ERS) joined forces to publish…
(Disclaimer: This article is for scientific purposes only, and the information in the following content has been processed to protect patient privacy)Abstract: The patient developed an intermittent cough with no…
Adenocarcinoma accounts for about 20% of all lung cancer patients and about 50% of female patients, some with neuroendocrine differentiation. Adenocarcinoma often presents as a peripheral type lung parenchymal mass.…